FiercePharmaOriginal article
{"a":[{"_":"Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis","$":{"href":"/pharma/xpovio-mulligan-endometrial-cancer-comes-short-karyopharm-presses-myelofibrosis","hreflang":"en"}}]}
Data ReadoutnegativeXpovioXpovioNegative
AI Analysis
Summary
Karyopharm reported negative trial data for Xpovio in endometrial cancer but plans to continue advancing the XPO1 inhibitor in myelofibrosis despite investor disappointment from a previous March dataset.
Outcome Details
Xpovio failed to meet expectations in endometrial cancer indication
Importance:6/10
Sentiment:
-0.60
oncologyclinical_trial_failuredrug_developmentXPO1_inhibitor
Related Companies
Read the original article
Published by FiercePharma on July 31, 2026 9:36 AM
